J3241 Injection. teprotumumab-trbw 10 milligrams
Also known as: teprotumumab, Tepezza, IGF-1 receptor inhibitor
Teprotumumab-trbw (Tepezza) 10 milligram injection is a human insulin-like growth factor-1 receptor inhibitor used for thyroid eye disease (Graves' ophthalmopathy).
In Plain Language
eye disease injection; Graves' eye treatment
Clinical Context
Indicated for thyroid eye disease (Graves' ophthalmopathy) to reduce proptosis and improve eye symptoms. Inhibits insulin-like growth factor-1 receptor signaling. Administered intravenously every 3 weeks for 8 weeks.
RVU Information
CPT J3241 does not have a physician work RVU assigned by CMS. This is typical for supply, drug, and equipment codes — reimbursement is based on Average Sales Price (ASP), fee schedules, or payer contracts rather than the RVU system.
Billing & Documentation
J-codes represent drugs administered by a healthcare provider (not self-administered). Documentation must include the drug name, dosage, route of administration, and medical necessity. Most payers require the National Drug Code (NDC) on the claim. Bill the appropriate administration code (96365-96379) in addition to the drug code.
Specialties
Frequently Asked Questions
What is CPT code J3241?
CPT J3241 (Injection. teprotumumab-trbw 10 milligrams) is a J Codes (Drugs) code. Teprotumumab-trbw (Tepezza) 10 milligram injection is a human insulin-like growth factor-1 receptor inhibitor used for thyroid eye disease (Graves' ophthalmopathy).
How is J3241 administered?
CPT J3241 is administered by a healthcare provider, typically via injection or infusion. Indicated for thyroid eye disease (Graves' ophthalmopathy) to reduce proptosis and improve eye symptoms. Inhibits insulin-like growth factor-1 receptor signaling. Administered intravenously every 3 weeks for 8 weeks. It is used by Endocrinology, Ophthalmology, Infusion Centers.
When is CPT J3241 used?
Indicated for thyroid eye disease (Graves' ophthalmopathy) to reduce proptosis and improve eye symptoms. Inhibits insulin-like growth factor-1 receptor signaling. Administered intravenously every 3 weeks for 8 weeks.
Track This Code in RVU Edge
Log procedures, calculate wRVUs, and benchmark against MGMA data — all in one app.
CPT® is a registered trademark of the American Medical Association. Data sourced from CMS Physician Fee Schedule RVU26A. Descriptions, synonyms, and clinical context are original content by RVU Edge.